Sera Prognostics Inc., a Salt Lake City, UT–based company that develops tests to diagnose preterm birth and other pregnancy complications, has raised $19.3m in Series A funding.
The round was led by venture capital firms InterWest Partners, Domain Associates and Catalyst Health Ventures, with participation from UpStart Life Sciences Capital, and new investor Osage University Partners.
The company intends to use the funds for clinical trials and for the commercial launch of its preterm birth diagnostic test.
In conjunction with the funding, Doug Fisher, M.D. of InterWest Partners, Kim P. Kamdar, Ph.D. of Domain Associates and Joshua Phillips of Catalyst Health Ventures will be joining Sera’s Board.
The company also appointed Gregory C. Critchfield, M.D., former president of Myriad Genetic Laboratories, Inc. and current Chairman of Sera’s Board of Directors, to CEO.